MedTrace Logo

A Study of SGN-ALPV in Advanced Solid Tumors

NCT05229900 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2025-02-10

No results posted yet for this study

Summary

This study will test the safety of a drug called SGN-ALPV in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease.

Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

This study will have three parts. Parts A and B of the study will find out how much SGN-ALPV should be given to participants. Part C will use the dose and schedule found in Parts A and B to find out how safe SGN-ALPV is and if it works to treat solid tumor cancers.

Conditions

  • Ovarian Neoplasms
  • Endometrial Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Stomach Neoplasms
  • Gastroesophageal Junction Carcinoma
  • Uterine Cervical Neoplasms
  • Testicular Neoplasms

Interventions

DRUG

SGN-ALPV

Given into the vein (IV; intravenously)

Sponsors & Collaborators

  • Seagen Inc.

    lead INDUSTRY

Principal Investigators

  • Suzanne McGoldrick, MD · Seagen Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-21
Primary Completion
2023-12-13
Completion
2023-12-13
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05229900 on ClinicalTrials.gov